title: [Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa].
abstract: BACKGROUND
  Pseudomonas aeruginosa is a common cause of serious infections in hospitalized patients and is associated with high rates of hospital morbidity and mortality.
  
  
  OBJECTIVE
  The aim of this study was to identify the risk factors of nosocomial infections caused by piperacillin-tazobactam-resistant P.aeruginosa (PT-RPA).
  
  
  METHODS
  A case-control study was conducted in the Clinical Centre Kragujevac from January 2010 to December 2011.
  
  
  RESULTS
  In the observed period, 79 (38.16%) patients had PT-RPA infections, while 128 (61.84%) patients had infections caused by piperacillin-tazobactam-sensitive P. aeruginosa (PT-SPA). Pneumonia was more frequently found in the PT-RPA group (55.70%) (p < 0.05), whereas urinary tract infections were more frequent in the group of patients with PT-SPA infections (26.56%) (p < 0.01). Multivariate analysis was used to identify an injury on admission (OR = 3.089; 95% CI = 1.438-6.635; p = 0.004), administration of imipenem (OR = 15.027; 95% CI = 1.778-127.021; p = 0.013), meropenem (OR = 2.618; 95% CI = 1.030-6.653; p = 0.043), ciprofloxacin (OR = 3.380; 95% CI = 1.412-8.090; p = 0.006), vancomycin (OR = 4.294; 95% CI = 1.477-12.479; p = 0.007), piperacillin-tazobactam (OR = 4.047; 95% CI = 1.395-11.742; p = 0.010) as independent risk factors associated with PT-RPA infection.
  
  
  CONCLUSIONS
  In hospitalized patients, the risk of PT-RPA infections is associated with previous administration of imipenem, meropenem, ciprofloxacin, vancomycin, piperacillin-tazobactam, and the presence of injury on admission.
authors.affiliation: Department of Infectious Diseases, Clinical Center of Kragujevac, Kragujevac, Serbia. mdjordjevic25@SB
authors.forename: Zorana
authors.initials: Z
authors.lastname: Djordjević
authors.affiliation: Department of Infectious Diseases, Clinical Center of Kragujevac, Kragujevac, Serbia.
authors.forename: Olgica
authors.initials: O
authors.lastname: Gajović
authors.affiliation: Department of Infectious Diseases, Clinical Center of Kragujevac, Kragujevac, Serbia.
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Mijailović
authors.affiliation: Faculty of Medicine, University of Pristina, Kosovska Mitrovica, Serbia.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Ilić
authors.affiliation: Faculty of Medicine, University of Pristina, Kosovska Mitrovica, Serbia.
authors.forename: Radojica
authors.initials: R
authors.lastname: Stolić
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D011550:Pseudomonas aeruginosa; D012307:Risk Factors; D013845:Thienamycins / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077725:Piperacillin, Tazobactam Drug Combination; D015378:Imipenem; D010397:Penicillanic Acid; D000077731:Meropenem; D010878:Piperacillin